Company / Financials
4D Molecular Therapeutics, Inc. Financials
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$37.0K
FY2025 · -99.8% YoY
Net Income
-$160.9M
FY2025 · -59.5% YoY
Profit Margin
-434778.4%
FY2025 · net income / revenue
ROE
-31.5%
FY2025 · return on equity
Total Assets
$566.7M
FY2025
Total Debt
-
FY2025
Equity
$510.6M
FY2025
ROA
-28.4%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 3.26 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$37.0K-99.8% YoYNet Income HistoryProfit after all expenses and taxes-$160.9M-59.5% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$187.8M-66.4% YoYSG&A Expense HistorySelling, general, and administrative expenses$46.6M+27.6% YoYR&D Expense HistoryResearch and development spending$141.3M+45.5% YoYIncome Tax HistoryTotal income tax expense$0EPS (Basic) HistoryBasic earnings per share-$2.98-15.5% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$2.98-15.5% YoYShares Outstanding HistoryWeighted average diluted shares outstanding45.8M+6.3% YoYTotal Assets HistoryTotal value of all assets owned$566.7M+1.1% YoY